| Identification | Back Directory | [Name]
BENZOIC ACID, 3-FLUORO-4-[[(2R)-HYDROXY(5,6,7,8-TETRAHYDRO-5,5,8,8-TETRAMETHYL-2-NAPHTHALENYL)ACETYL]AMINO]- | [CAS]
262433-54-5 | [Synonyms]
Benzoic acid, 3-fluoro-4-[[(2R)-2-hydroxy-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)acetyl]amino]- | [Molecular Formula]
C23H26FNO4 | [MDL Number]
MFCD10565938 | [MOL File]
262433-54-5.mol | [Molecular Weight]
399.46 |
| Hazard Information | Back Directory | [Uses]
BMS270394 is a nuclear retinoic acid receptor (RAR-γ) agonist with the EC50 values of 30 nM and 400 nM for humanRAR-γ and RAR-β, respectively[1]. | [Biological Activity]
BMS 270394 is an agonist of retinoic acid receptor γ (RARγ; EC50 = 30 nM in a transactivation assay) and the active enantiomer of BMS 189961 .1 It is selective for RARγ over RARβ (EC50 = 400 nM) and is inactive at RARα. BMS 270394 synergizes with paclitaxel to inhibit the growth of MCF-7 breast and OVCAR-3 ovarian cancer, as well as SqCC/Y1 head and neck squamous cell carcinoma, cells.2 | [IC 50]
RXR γ: 30 nM (EC50); RXR β: 400 nM (EC50) | [storage]
-20°C | [References]
1.Klaholz, B.P., Mitschler, A., Belema, M., et al.Enantiomer discrimination illustrated by high-resolution crystal structures of the human nuclear receptor hRARγProc. Natl. Acad. Sci. USA97(12)6322-6327(2000)
2.Vivat-Hannah, V., You, D., Rizzo, C., et al.Synergistic cytotoxicity exhibited by combination treatment of selective retinoid ligands with taxol (Paclitaxel)Cancer Res.61(24)8703-8711(2001)
|
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
|